About
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.
Current Value
$1.021 Year Return
Current Value
$1.021 Year Return
Key Details
Market Cap
$75.40M
P/E Ratio
-0.53
1Y Stock Return
-79.54%
1Y Revenue Growth
-
Dividend Yield
0.00%
Price to Book
0.3
Strategies that include VTYX
Double maintains 1 strategies that include VTYX - Ventyx Biosciences, Inc.
Medium risk
$13,000
0.00%
Health Care Sector
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
348
Stock's related to VTYX
The stocks that are correlated to VTYX - Ventyx Biosciences, Inc. are IMNM, ARCT, KYMR, KOD, AGIO
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
 IMNMImmunome, Inc. | 41.41% | $583.44M | -68.94% | 0.00% |
| 39.52% | $276.62M | -68.85% | 0.00% | |
| 39.51% | $1.71B | -29.01% | 0.00% | |
| 37.70% | $140.84M | -37.47% | 0.00% | |
| 37.12% | $1.63B | -0.11% | 0.00% | |
| 37.11% | $151.87M | -88.25% | 0.00% | |
 BHVNBiohaven Ltd. | 37.08% | $2.42B | -54.71% | 0.00% |
| 36.69% | $671.77M | -75.23% | 0.00% | |
| 35.85% | $2.13B | -40.76% | 0.00% | |
| 35.80% | $1.22B | +22.77% | 0.00% | |
| 35.77% | $311.52M | -54.38% | 0.00% | |
| 35.64% | $88.24M | -89.02% | 0.00% | |
| 35.56% | $933.38M | -55.31% | 0.00% | |
 XNCRXencor, Inc. | 35.44% | $691.94M | -54.37% | 0.00% |
 CTSCTS Corp. | 35.43% | $1.26B | -6.74% | 0.43% |
| 35.12% | $1.17B | -13.14% | 0.00% | |
| 34.91% | $7.19B | -12.42% | 0.00% | |
| 34.69% | $2.36B | +4.68% | 4.30% | |
 RGNXREGENXBIO, Inc. | 34.57% | $353.11M | -65.19% | 0.00% |
| 34.53% | $369.07M | -74.12% | 0.00% | |
ETF's related to VTYX
The ETFs that are correlated to VTYX - Ventyx Biosciences, Inc. are CPRJ, XBI, IWC, RSPA, GNOM
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 57.71% | $48.38M | 0.69% | |
| 46.84% | $4.76B | 0.35% | |
| 43.86% | $797.08M | 0.6% | |
| 43.39% | $292.67M | 0% | |
| 41.30% | $47.13M | 0.5% | |
| 41.07% | $936.86M | 0.75% | |
| 39.32% | $10.72B | 0.24% | |
| 38.84% | $144.85M | 0.79% | |
| 38.67% | $10.92B | 0.07% | |
| 38.51% | $62.65B | 0.19% | |
| 38.45% | $3.28B | 0.15% | |
| 37.98% | $5.61B | 0.45% | |
| 37.13% | $15.94B | 0.04% | |
| 36.75% | $1.95B | 0.2% | |
| 36.59% | $158.14M | 0.35% | |
| 36.23% | $833.42M | 0.6% | |
| 36.18% | $10.95B | 0.24% | |
| 36.12% | $514.19M | 0.2% | |
| 35.98% | $1.10B | 0.31% | |
| 35.44% | $317.59M | 0.79% | |
News
Yahoo
Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-rec
Yahoo
Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2VTX3232 in participants with obesity and cardiometabolic risk factors in H2VTX3232 biomarker study in patients with early Parkinson’s disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: V
Yahoo
Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patien
Yahoo
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Event: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceLocation: VirtualDate: We
Yahoo
Ventyx Biosciences (VTYX) highlighted its 2025 pipeline strategy and provided clinical updates on its NLRP3 inhibitor portfolio, including VTX2735 and VTX3232. First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025; Phase 2 trial of VTX2735 in participants with recurrent pericarditis expected to initiate in January, with topline data expected in H2 2025; Topline data from ongoing Phase 2 biomarker tr
Yahoo
First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with recurrent pericarditis expected to initiate in January, with topline data expected in H2 2025 Topline data from ongoing Phase 2 biomarker trial of VTX3232 in participants with early Parkinson’s disease expected in H1 2025 Cash, cash equivalents and marketable securities balance of $252.9M as of Decemb
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds